Minority Population

Presented By: 

About the Program

• Program Overview
• Learning Objectives and Program Details
• Intended Audience
• Accreditation Statement
• Credit Designation Statement
• Course Directors
• Faculty
• Full Disclosure Policy Affecting CME Activities
• Off-label Product Discussion
• Request for Program Slides and Review
• Method to Participate and Obtain Continuting Medical Education Credit

Program Overview

Recent data from the Centers of Disease Control, demonstrate that HIV/AIDS continues to increase disproportionately among minority populations. Despite African-Americans making up only 12% of the US population, in 2006 almost half of HIV/AIDs cases were African-American and 48% of new AIDS cases reported were in African-American adults and adolescents (Needs Source A, Recent Research).

Further, numerous studies indicate that a significant number of minority patients are not receiving antiretroviral therapy when they should  and that minority populations infected with HIV are less likely to get the other care they need – including general HIV care and treatment for comorbities – than other populations of HIV-positive patients. This care gap between minority and non-minority HIV-positive patients is a contributing factor in the higher HIV-related mortality seen in minority patients.

This case-based educational program is designed to educate health care providers regarding (1) the need to address and improve the health care of minority HIV-positive patients, (2) appropriate steps that can and should be taken to make sure that minority HIV-positive patients become engaged with health care – including being tested for HIV and, if positive, seeking appropriate medical care – and receive regular clinical monitoring, (3) how to optimize the HIV-positive minority patient’s access to antiretroviral and other therapies; and (4) how to manage some of the challenges that may occur with higher frequency in HIV-positive minority patients, including mental health and social issues.

This program is for health care providers who treat HIV-positive patients and there are no prerequisites.

Back to Top

Learning Objectives and Program Details

Upon completion of the program, participants should be:

1. more knowledgeable regarding the importance of individualizing ARV therapy for minority populations;

2. able to explain the role individualizing ARV therapy has in improving treatment outcomes in minority populations;

3. able to explain and use in clinical settings the skills needed to gather knowledge regarding the patient and establish a trusting relationship that furthers the exchange  of information between clinician and patient needed to accomplish individualization of care in minority populations;

4. able to apply in clinical practice the concepts important in individualizing ARV therapy in minority populations, including considering and weighing the characteristics of the ARV therapy options available and applying this knowledge to the characteristics of the individual patient to arrive at the optimal choice of ARV therapy for that individual.

Release Date: February 1, 2010
Expiration Date: February 1, 2011

Estimated time to complete this activity: 1 hour

Back to Top

Intended Audience

This activity is intended for physicians, physicians' assistants, advanced practice nurses, and other healthcare professionals involved in the treatment and management of patients with HIV infection. There are no prerequisites.

Back to Top

Accreditation Statement

The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Back to Top

Credit Designation Statement

The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should only claim credit commensurate with the extent of their participation in the activity.

Back to Top   

Course Directors

John Bartlett, MD
Professor of Medicine,
Johns Hopkins School of Medicine
Baltimore, Maryland

Edwin DeJesus, MD
Medical Director,
Orlando Immunology Center
Orlando, Florida

Luther A. Virgil, Jr., MD
Chief Medical Officer,
National Minority Clinical Research Association (NMCRA)
Fairfield, New Jersey 

Faculty

Ian Frank, MD
Associate Professor of Medicine,
Director, Antiretroviral Clinical Research
University of Pennsylvania
Philadelphia, Pennsylvania

Wilbert Jordan, MD
Medical Director,
Charles Drew Medical Center
Los Angeles, California

Calvin J. Cohen, MD, MS
Research Director,
CRI New England
Clinical Instructor,
Harvard Medical School
Boston, Massachusetts

Richard A. Elion , MD
Associate Professor of Clinical Medicine,
George Washington University Medical Center
Washington, DC

Rafael E. Campo, MD
Professor of Clinical Medicine
Division of Infectious Diseases
University of Miami School of Medicine
Jackson Memorial Hospital
Miami, Florida

M. Keith Rawlings, MD
Medical Director
AIDS/Arms Peabody Health Center
Dallas, Texas

Full Disclosure Policy Affecting CME Activities

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine to require the disclosure of the existence of any relevant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following:   

Dr. John Bartlett:

• Consulting Agreements: Tibotec; Merck
• Honorarium Agreements: Abbott

Dr. Edwin DeJesus:

• Sources of Funding for Research: Abbott; Achillion; Avexa; Boehringer Ingelheim; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Hoffman LaRoche Laboratories; Merck & Co.; Pfizer; Schering Plough; Taimed; Tobira; Tibotec; Vertex
• Consulting/Honorarium Agreements: Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck & Co.; Tiborec; Vertex
• Speakrs' Bureau: Gilead Sciences; Merck & Co.; Tibotec; Virco

Dr. Luther Virgil:

• Nothing to disclose

Dr. Ian Frank:

• Sources of Funding for Research: Merck & Co.
• Consulting Agreements: Abbott; GlaxoSmithKline; Gilead; Pfizer;
• Honorarium Agreements: Bristol-Myers Squibb; Gilead; Pfizer; Tibotec
• Speakers' Bureau: Gilead; Tibotec

Dr. Wilbert Jordan:

• Nothing to Disclose

Dr. Calvin Cohen:

• Sources of Funding for Research: GlaxoSmithKline; Tibotec; Bristol-Myers Squibb; Pfizer; Gilead; Merck & Co.
• Consulting Agreements: Bristol-Myers Squibb; Gilead; Merck & Co.; Tibotec; Myriad; Tobira
• Speakers' Bureau/Honorarium Agreements: Bristol-Myers Squibb; Gilead; Merck & Co.; Tibotec

Dr. Richard Elion:

• Sources of Funding for Research: Tobira; Tibotec; Bristol-Myers Squibb; GlaxoSmithKline; Gilead; Rapid Pharmaceuticals
• Consulting Agreements: GlaxoSmithKline; Gilead; Merck & Co.; Tibotec; Rapid Pharmaceuticals
• Speakers' Bureau/Honorarium Agreements: Bristol-Myers Squibb; Gilead; Merck & Co.; Tibotec; GlaxoSmithKline

Dr. Rafael Campo:

• Sources of Funding for Research: Gilead; Merck & Co.; Pfizer
• Consulting Agreements: Abbott; Gilead; Merck & Co.; Tibotec; Virco
• Speakers' Bureau: Bristol-Myers Squibb; Abbott; Merck & Co.; Virco
• Other: Wife is an employee of Merck & Co..  Ms. Campo is a manager in the Merck Health Services Group asthma and diabetes division.

Dr. M. Keith Rawlings:

• Sources of Funding for Research: Gilead; NIH
• Consulting Agreements: Abbott; Gilead; Ardea Biosciences
• Honorarium Agreements: Abbott; BI; Bristol-Myers Squibb; GlaxoSmithKline; Gilead; Pfizer; Tibotec

Back to Top

Off-label Product Discussion

All faculty presenters have disclosed that thier presentation will not reference any unlabelled/unapproved use of any products.

Request for Program Slides and Review

To request a copy of the program slides as well as further education on how to use the slides please Click Here to fill out a content request form.

Method to Participate and Obtain Continuting Medical Education Credit

In order to receive credit, participants must view the entire activity and complete a post test and activity evaluation online. Upon a successful score of 70% on the post test and completion of the evaluation, participants may print out their certificate. Participants may access the program, post test and evaluation for this activity by clicking the link below:

---

Opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME program. CME collects only the information necessary to provide you with the services that you request.

Copyright © 2008 The Johns Hopkins University School of Medicine. All rights reserved.